



## PRESS RELEASE

### Oncodesign announces its financial calendar for 2017

**Dijon (France), February 2, 2017 – ONCODESIGN (FR0011766229 - ALONC)**, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious diseases with no known effective treatment, announces its financial calendar for 2017.

- Thursday, March 30, 2017:** Publication of full year 2016 results (after market)
- Thursday, June 29, 2017:** Annual Shareholders' Meeting
- Thursday, July 20, 2017:** Publication of half year 2017 revenues (after market)
- Tuesday, September 19, 2017:** Publication of half year 2017 results (after market)

Beyond these periodicals, investors are invited to consult the website of the company ([www.oncodesign.com](http://www.oncodesign.com)) where information is regularly updated. All corporate and financial information on the company is available on the company's website, in the Finance' section.

This schedule is indicative and subject to change.

**About d'ONCODESIGN :** [www.oncodesign.com](http://www.oncodesign.com)

Founded over 20 years ago by Dr Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biotechnology company that maximises the pharmaceutical industry's chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment. With its unique experience acquired by working with more than 600 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modelling and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over \$46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb, Ipsen and UCB. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 165 employees and subsidiaries in Canada and the USA.

#### Contacts

**Oncodesign**  
Philippe Genne  
Chairman and CEO  
Tel: +33 (0)3 80 78 82 60  
[investisseurs@oncodesign.com](mailto:investisseurs@oncodesign.com)

**NewCap**  
Investor & Press Relations  
Julien Perez / Nicolas Merigeau  
Tel: +33 (0)1 44 71 98 52  
[oncodesign@newcap.eu](mailto:oncodesign@newcap.eu)

**ALONC**  
**LISTED**  
**ALTERNEXT**